4/26/2011

Nano Terra and Kadmon Pharmaceuticals intend to create a joint venture, NT Life Sciences, to work on the former's Pharmacomer drug-discovery platform and three of its enzyme-targeting compounds. Kadmon will have exclusive global rights to the investigational drugs and the technology.

Related Summaries